Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone

Journal of the American Geriatrics Society

Volumn 64, Issue 3, 2016, Pages 672-674

  Carbonella, Angela ^a   Berardi, Giorgia ^a   Petricca, Luca ^a   Biscetti, Federico ^a   Alivernini, Stefano ^a   Bosello, Silvia Laura ^a   Fedele, Anna Laura ^a   Ferraccioli, Gianfranco ^a   Gremese, Elisa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; PREDNISONE; IMMUNOSUPPRESSIVE AGENT;

CATARACT; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; FOLLOW UP; FRACTURE; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; LETTER; OSTEOPOROSIS; OUTCOME ASSESSMENT; PNEUMONIA; RECURRENCE RISK; TREATMENT RESPONSE; AGED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; FEMALE; MALE; RETROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; AGED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; RETROSPECTIVE STUDIES;

EID: 84961828376     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.14004     Document Type: Letter

References (10)

1. Mukhtyar C, Guillevin L, Cid MC, et al., European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323.
2. Kötter I, Henes JC, Wagner AD, et al., Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30: S114-S129.
3. Salvarani C, Macchioni PL, Tartoni PL, et al., Polymyalgia rheumatica and giant cell arteritis: A 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 205-215.
4. Hoffman GS, Cid MC, Hellmann DB, et al., A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-1318.
5. Jover JA, Hernández-García C, Morado IC, et al., Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-114.
6. Mahr AD, Jover JA, Spiera RF, et al., Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797.
7. Henes JC, Mueller M, Pfannenberg C, et al., Cyclophosphamide for large vessel vasculitis: Assessment of response by PET/TC. Clin Exp Rheumatol 2011; 29: S43-S48.
8. Quartuccio L, Maset M, De Maglio G, et al., Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology 2012; 51: 1677-1686.
9. Fries JF, Hunder GG, Bloch DA, et al., The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 8: 1135-1136.
10. Alba MA, García-Martínez A, Prieto-González S, et al., Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. Seminars Arthritis Rheum 2014; 43: 772-777.